false 0001104506 NASDAQ 0001104506 2026-07-16 2026-07-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16, 2026
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)

Virginia | 000-30739 | 54-1972729
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)

700 US Highway 202/206 Bridgewater, New Jersey |  | 08807 (Zip Code)
(Address of principal executive offices) |  |

Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.01 per share | INSM | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 — | Regulation FD Disclosure.

On July 16, 2026, Insmed Incorporated (the “Company”) issued a press release announcing 12-month safety and efficacy data from its ongoing open-label extension study of treprostinil palmitil inhalation powder in patients with pulmonary arterial hypertension (the “OLE Study”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The Company will host a conference call to discuss the 12-month data of the OLE Study on July 16, 2026, at 8:00 a.m., Eastern Time, and a live webcast of the call will be available through the investor relations section of the Company’s website. A copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 — | Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. |  | Description
99.1 |  | Press release issued by Insmed Incorporated on July 16, 2026.
99.2 |  | Insmed Incorporated July 16, 2026 12-Month OLE Study Presentation
104 |  | Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 16, 2026 | INSMED INCORPORATED
| By: | /s/ Michael A. Smith
| Name: | Michael A. Smith
| Title: | Chief Legal Officer and Corporate Secretary